{"entity":{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","aka":[],"tldr":"Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.","summary":"Catherine Thieblemont (Hôpital Saint-Louis, Paris) was principal investigator of EPCORE NHL-1, the pivotal trial showing the subcutaneous CD3xCD20 bispecific epcoritamab produces deep, durable responses in relapsed or refractory large B-cell lymphoma, leading to its approval. She has led LYSA trials in marginal zone and elderly DLBCL and co-chairs the EPCORE programme moving bispecifics into earlier lines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab"}],"tags":["lymphoma","bispecific","lysa"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["cd20","cd3"],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":["epcore-nhl-1","epcore-dlbcl-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-epcore-nhl-1-epcoritamab-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Hemato-Oncology, Hôpital Saint-Louis, Paris; Professor, Université Paris Cité","institutionId":"aphp-nord-cancer-institute","specialisms":["Aggressive lymphoma","Bispecific antibodies","Marginal zone lymphoma","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab"}],"papers":[{"title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial (EPCORE NHL-1)","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.01725"},{"title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (REMARC)","journal":"JCO","year":2017,"doi":"10.1200/JCO.2017.72.6984"},{"title":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","journal":"Journal of Clinical Oncology","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORE%20NHL-1%20epcoritamab%20large%20B-cell%20lymphoma%20Thieblemont%20JCO%202023"}]},"route":"/people/catherine-thieblemont/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"institution":[{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/"}],"trial":[{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/"},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/"},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/"},{"id":"remarc","kind":"trial","name":"REMARC","route":"/trials/remarc/"}],"paper":[{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/"},{"id":"paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","kind":"paper","name":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","route":"/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/"},{"id":"paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","kind":"paper","name":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","route":"/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/"},{"id":"paper-elara-tisagenlecleucel-follicular-nat-med-2022","kind":"paper","name":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","route":"/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}